Bio-Rad Laboratories, Inc. Class A Common Stock (BIO)
327.07
-15.06 (-4.40%)
Bio-Rad Laboratories is a global leader in life science research and clinical diagnostics, providing a wide array of innovative products and solutions that empower scientists and healthcare professionals
The company develops and manufactures instruments, software, reagents, and consumables for various applications, including research in genomics, proteomics, and cellular biology, as well as diagnostic testing for infectious diseases, oncology, and blood transfusion safety. Through its commitment to advancing scientific discovery and improving patient outcomes, Bio-Rad plays a critical role in facilitating important breakthroughs in healthcare and research.
480 out of 500 S&P 500 companies are trading below analysts' price targets, indicating potential profit opportunities. April has been bleak for the market, but some undervalued stocks may be worth buying. Top 5 stocks with biggest gap between price and target: CCL, BIO, WBD, CZR, CCO.
Wall Street takes pause after stronger-than-expected producer inflation report, potentially delaying Fed rate cuts and impacting major indices and stocks.
Fifty-six percent of S&P 500 companies have shown positive performance in 2023 and 44% retreated Moderna Inc. (NASDAQMRNA) offers the highest upside potential (58%).
Bio-Rad Laboratories Inc (NYSEBIO) shares are trading lower after the company lowered its annual revenue growth forecast, citing the uncertain pace of the biopharma sector's recovery and the
